丙种球蛋白治疗重症肺炎合并血小板减少症的疗效分析

王春亚; 张小玲; 王小闯

doi:10.13201/j.issn.1009-5918.2018.04.011

丙种球蛋白治疗重症肺炎合并血小板减少症的疗效分析

- 西安交通大学第二附属医院重症医学科(西安, 710004)

详细信息

通讯作者: 王春亚, E-mail:uncanny2006@163.com

中图分类号: R563.1

收稿日期: 2018-03-21

The efficacy of IVIG in the treatment of severe pneumonia with thrombo-cytopenia

- Department of Critic Care Medicine, the Second Affiliated Hospital of Xi'an Jiaotong University Medical College, Xi'an, 710004, China

More Information

Corresponding author: WANG Chunya, E-mail: uncanny2006@163.com

Received Date: 21 March 2018

摘要

摘要: 目的: 观察丙种球蛋白 (IVIG) 治疗重症肺炎合并血小板减少的疗效及安全性。方法: 选取2014-08-2017-12期间在我院接受治疗的48例重症肺炎合并血小板减少症患者, 随机分为对照组 (28例) 和治疗组 (20例), 对照组给予常规治疗, 治疗组在常规治疗基础上给予静脉点滴IVIG (0.4g·kg^-1·d^-1), l次/d, 连用3d, 并观察两组患者血小板计数、机械通气时间、氧合指数改善情况、危重症评分 (APACHEⅡ)、28d病死率及药物不良反应情况。结果: 治疗组血小板上升幅度高于对照组、氧合指数及病情严重程度改善情况优于对照组、机械通气时间短于对照组, 且差异有统计学意义 (P<0.05或P<0.01);两组间28d病死率无差别, 用药过程中未发现有药物不良反应。结论: IVIG治疗重症肺炎合并血小板减少症具有一定疗效, 且安全性好。
- 丙种球蛋白 /
- 重症肺炎 /
- 血小板减少
Abstract: Objective: To observe the efficacy and safety of IVIG in the treatment of severe pneumonia with thrombocytopenia.Method: Forty-eight cases of severe pneumonia complicated with thrombocytopenia from August2014 to December2017 in our hospital were randomly divided into control (n=28) and treatment (n=20) groups, patients in the control group were given routine treatment, while those in the treatment group were administered with IVIG (0.4 g·kg^-1·d^-1) for 3 days.The changes of platelet count, oxygenation index, mechanical ventilation time, APACHEⅡscore, 28 d mortality and drug adverse reaction were observed.Result: The platelet counts of treatment group increased more than the control group, the oxygenation indexes were better than those of control group, the mechanical ventilation time was shorter than the control group (P<0.05 or P<0.01), there were no significant difference of 28 dmortality between the two groups, and adverse drug reaction was not found in the treatment group.Conclusion: IVIG is effective and safe in the treatment of severe pneumonia with thrombocytopenia.
- IVIG /
- severe pneumonia /
- thrombocytopenia

HTML全文

参考文献(15)

[1]	Vandijck D M, Blot S L, De Waele J J, et al.Thrombocytopenia and outcome in critically ill patients with bloodstream infection[J].Heart Lung, 2010, 39:21-26.
[2]	王淦楠, 张刚, 张劲松.凝血及纤溶功能紊乱与脓毒性休克严重程度及预后的关系[J].临床急诊杂志, 2016, 17 (2):111-114.
[3]	中国医师协会急诊医师分会.急诊成人社区获得性肺炎诊治专家共识[J].中国急救医学, 2011, 31 (10):865-871.
[4]	Kraemer B F, Campbell R A, Schwertz H, et al.Bacteria differentially induce degradation of Bcl-xL, a survival protein, by human platelets[J].Blood, 2012, 120:5014-5020.
[5]	Thiery-Antier N, Binquet C, Vinault S, et al.Is Thrombocytopenia an Early Prognostic Marker in Septic Shock[J]?Crit Care Med, 2016, 44, 764-772.
[6]	Garraud O, Hamzeh-Cognasse H, Pozzetto B, et al.Bench-to-bedside review:Platelets and active immune functions-New clues for immunopathology[J]?Crit Care, 2013, 17, 236-236.
[7]	Borge O J, Ramsfjell V, Veiby O P, et al.Thrombopoietin but not erythropoietin promotes viability and inhibits apoptosis of multipotent murinehematopoietic progenitor cells in vitro[J].Blood, 1996, 88:2859-2570.
[8]	吴田田, 姚咏明.脓毒症免疫紊乱及其临床意义[J].解放军医学杂志, 2017, 42 (2):95-102.
[9]	Bonagura V R.Using intravenous immunoglobulin (IVIG) to treat patients with primary immune deficiency disease[J].J Clin Immunol, 2013, 33:S90-S94.
[10]	中国医师协会急诊医师分会, 中国急性感染联盟.2015年中国急诊社区获得性肺炎临床实践指南[J].中华急诊医学杂志, 2015, 24 (12):1324-1344.
[11]	陈海莲.丙种球蛋白治疗老年重症肺炎的疗效分析[J].湖北理工学院学报, 2014, 30 (6):57-59.
[12]	李丕宝.老年重症医院获得性肺炎并发弥漫性肺泡出血综合征15例临床分析[J].临床急诊杂志, 2016, 17 (1):77-78.
[13]	黄天然, 苏木珍, 吕波, 等.免疫球蛋白治疗脓毒血症相关性血小板减少症的疗效[J].锦州医科大学学报, 2017, 38 (2):19-22.
[14]	窦琳, 王勇强, 曹书华, 等.免疫球蛋白对脓毒症患者血管内皮功能和血小板计数的影响[J].中国急救医学, 2007, 27 (10):869-971.
[15]	龙怀聪, 肖邦榕, 刘跃建.162例成人重症肺炎临床特点及死亡危险因素分析[J].实用医院临床杂志, 2011, 8 (4):75-78.